Latest news about AscellaHealth
Here are some of the most recent media mentions. Use them in your sales prospecting to qualify a prospect's buyer intent and personalize outreach with the latest company updates
AscellaHealth released its Q1 2025 Specialty & Rare Pipeline Digest™ on April 2, 2025, providing essential clinical drug updates on new, pending, and upcoming specialty and rare disease drug launches, biosimilars, and cell and gene therapies. The digest highlights key products impacting healthcare and drug spend, including biosimilars for Stelara and new therapeutic options for ATTR-CM, schizophrenia, and hemophilia[2][4][5].
AscellaHealth announced key executive promotions on April 15, 2025, with Donovan Quill as chief strategy officer and Bob Gilkin as chief commercial and growth officer for the Life Sciences business unit, supporting strategic growth and integrating strengths with affiliate Actum Pharma to aid biopharma companies in developing and marketing therapies[2][3].
AscellaHealth will sponsor and lead a key discussion at the World Orphan Drug Congress USA 2025, held from April 22-24, 2025. Donovan Quill will lead a roundtable on “The Truths and Myths of Building a Patient-First Exclusive Distribution Program,” focusing on optimizing supply chain processes and patient access to therapies for rare conditions[5].
Open job positions at AscellaHealth
This company is actively hiring to fill these roles. Use this for sales prospecting if your solution assists, augments, or provides an alternative for the growing team and position.
Business Unit Controller
AI sales outreach emails you can send to AscellaHealth